US regulatory status: approved. Molecular target: Synaptosomal-associated protein 25.
- Target
- Synaptosomal-associated protein 25
- Mechanism
- Synaptosomal-associated protein 25 inhibitor
pharma · Metastatic Pancreatic Adenocarcinoma · Primary Biliary Cholangitis
Ipsen
Ipsen drug portfolio — 36 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
70, Rue Balard, Paris, Île-de-France 75015, FR HQ
6,584 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 70, Rue Balard, Paris, Île-de-France 75015, FR
- Employees
- 6,584
- Programs
- 27
- Drugs
- 36
- Patents
- 0
Ipsen pipeline
Portfolio lens on 36 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Ipsen drug portfolio — 36 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Ipsen in public FDA and regional records. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
botulinum toxin type a
Musculo-skeletal system (M03)Musculo-skeletal system (M03) compound in Ipsen's portfolio. Molecular target: Synaptosomal-associated protein 25.
- Target
- Synaptosomal-associated protein 25
- Mechanism
- Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme
-
cabozantinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Mechanism: Hepatocyte growth factor receptor inhibitor.
- Mechanism
- Hepatocyte growth factor receptor inhibitor
-
US regulatory status: approved. Molecular target: Hepatocyte growth factor receptor.
- Target
- Hepatocyte growth factor receptor
- Mechanism
- Hepatocyte growth factor receptor inhibitor
-
US regulatory status: approved.
-
Development asset linked to Ipsen in public FDA and regional records.
-
Development asset linked to Ipsen in public FDA and regional records.
-
Development asset linked to Ipsen in public FDA and regional records.
-
Development asset linked to Ipsen in public FDA and regional records.
-
Development asset linked to Ipsen in public FDA and regional records.
-
elafibranor
Alimentary tract and metabolism (A05)US regulatory status: approved. Molecular target: Peroxisome proliferator-activated receptor alpha.
- Target
- Peroxisome proliferator-activated receptor alpha
- Mechanism
- Peroxisome proliferator-activated receptor delta agonist
-
Development asset linked to Ipsen in public FDA and regional records.
-
Development asset linked to Ipsen in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
US regulatory status: approved. Molecular target: Peroxisome proliferator-activated receptor alpha.
- Target
- Peroxisome proliferator-activated receptor alpha
- Mechanism
- Peroxisome proliferator-activated receptor alpha agonist
-
Development asset linked to Ipsen in public FDA and regional records.
-
Development asset linked to Ipsen in public FDA and regional records.
-
Development asset linked to Ipsen in public FDA and regional records.
-
Development asset linked to Ipsen in public FDA and regional records.
-
Development asset linked to Ipsen in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA topoisomerase 1.
- Target
- DNA topoisomerase 1
- Mechanism
- DNA topoisomerase I inhibitor
-
US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.
- Target
- Lanosterol 14-alpha demethylase
- Mechanism
- Cytochrome P450 51 inhibitor
-
Development asset linked to Ipsen in public FDA and regional records. Mechanism: Somatostatin receptor 2 agonist.
- Mechanism
- Somatostatin receptor 2 agonist
-
odevixibat
Alimentary tract and metabolism (A05)US regulatory status: approved. Molecular target: Ileal sodium/bile acid cotransporter.
- Target
- Ileal sodium/bile acid cotransporter
- Mechanism
- Ileal bile acid transporter inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
palovarotene
Musculo-skeletal system (M09)US regulatory status: approved. Molecular target: Retinoic acid receptor gamma.
- Target
- Retinoic acid receptor gamma
- Mechanism
- Retinoic acid receptor gamma agonist
-
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
Development asset linked to Ipsen in public FDA and regional records.
-
Development asset linked to Ipsen in public FDA and regional records.
-
Development asset linked to Ipsen in public FDA and regional records.
-
Development asset linked to Ipsen in public FDA and regional records.
-
Development asset linked to Ipsen in public FDA and regional records.
-
Development asset linked to Ipsen in public FDA and regional records.
-
Development asset linked to Ipsen in public FDA and regional records.